Table 3. Meta-analysis of the relationship of the IL-1 polymorphisms with COPD risk.
| No. of studies | Dominant | Recessive | Homozygote | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Polymorphism | OR (95% CI) | Phet | Pz | OR (95% CI) | Phet | Pz | OR (95% CI) | Phet | Pz | |
| IL1B (-511)a | ||||||||||
| Total | 9 | 1.22 (0.84-1.75) | 0.002 | 0.293 | 0.94 (0.67-1.32) | 0.010 | 0.730 | 1.10 (0.65-1.85) | <0.001 | 0.734 |
| East Asians | 6 | 1.61 (1.13-2.31) | 0.061 | 0.009 | 1.13 (0.74-1.73) | 0.017 | 0.574 | 1.62 (0.91-2.88) | 0.005 | 0.105 |
| IL1B (-31)b | ||||||||||
| Total | 4 | 1.25 (0.79-1.96) | 0.101 | 0.340 | 0.80 (0.52-1.21) | 0.225 | 0.287 | 1.00 (0.52-1.95) | 0.065 | 0.993 |
| East Asians | 3 | 1.55 (1.14-2.11) | 0.842 | 0.006 | 0.87 (0.64-1.18) | 0.469 | 0.356 | 1.27 (0.87-1.87) | 0.599 | 0.221 |
| IL1B (+3954)c | ||||||||||
| Total | 4 | 1.16 (0.78-1.73) | 0.830 | 0.464 | 0.97 (0.32-2.88) | 0.486 | 0.951 | 1.02 (0.33-3.12) | 0.480 | 0.974 |
| East Asians | 3 | 1.16 (0.75-1.78) | 0.645 | 0.503 | 0.33 (0.01-8.19) | NA | 0.500 | 0.35 (0.01-8.54) | NA | 0.516 |
| IL1RN (VNTR)d | ||||||||||
| Total | 5 | 1.64 (0.99-2.73) | 0.241 | 0.056 | 2.59 (1.02-6.58) | 0.891 | 0.046 | 3.16 (1.23-8.13) | 0.800 | 0.017 |
| East Asians | 4 | 1.48 (0.77-2.83) | 0.146 | 0.241 | 2.60 (0.93-7.31) | 0.732 | 0.069 | 3.20 (1.13-9.12) | 0.605 | 0.029 |
CI, confidence interval; COPD, chronic obstructive pulmonary disease; IL-1, interleukin-1; NA, not available; OR, odds ratio; Phet, P-value for heterogeneity; Pz, P-value for overall effect.
aFor IL1B (-511) polymorphism: dominant (TT + TC vs CC), recessive (TT vs TC + CC) and homozygote (TT vs CC).
bFor IL1B (-31) polymorphism: dominant (CC + CT vs TT), recessive (CC vs CT + TT) and homozygote (CC vs TT).
cFor IL1B (+3954) polymorphism: dominant (TT + TC vs CC), recessive (TT vs TC + CC) and homozygote (TT vs CC).
dFor IL1RN (VNTR) polymorphism: dominant (22 + 2L vs LL), recessive (22 vs 2L + LL) and homozygote (22 vs LL).